MedElevator
Войти в исследования Diabetes, obesity & metabolism · 2026
Person-Reported and Continuous Glucose Monitoring (CGM) Recorded Hypoglycaemia in People With Insulin-Treated Type 2 Diabetes and Mild to Moderate Chronic Kidney Disease; Post Hoc Analysis From the Hypo-METRICS Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brøsen Julie M B, Malmsiø Daniel, Divilly Patrick, Martine-Edith Gilberte, Zaremba Natalie, Ali Namam, McCrimmon Rory J, Heller Simon, Evans Mark, de Galan Bastiaan, Mader Julia K, Renard Eric, Vaag Allan A, Choudhary Pratik, Pedersen-Bjergaard Ulrik, HypoRESOLVE Consortium
Аннотация
BACKGROUND AND AIMS: People with diabetes and chronic kidney disease (CKD) may be at increased risk of iatrogenic hypoglycaemia. We compared rates of sensor-detected (SDH) and person-reported hypoglycaemia (PRH) in people with insulin-treated Type 2 diabetes (T2D) with and without CKD in the Hypo-METRICS study.
MATERIALS AND METHOD: Insulin-treated T2D patients with > 1 hypoglycaemic episode within the last 3 months wore a blinded continuous glucose monitor (CGM) and recorded PRH on the bespoke Hypo-METRICS app for 10 weeks. SDH was defined as per consensus guidelines. The participants were grouped based on estimated glomerular filtration rate (eGFR), that is CKD 1 (eGFR ≥ 90 mL/min; n = 117), CKD 2 (eGFR 60-89 mL/min; n = 140), and CKD 3 (eGFR 30-59 mL/min; n = 56). We used descriptive statistics, Kruskal-Wallis rank sum tests, and a negative binomial models to control for confounders.
RESULTS: In total, 313 participants with T2DM were included. Median age increased with declining eGFR (p < 0.001). Median (IQR) events per week for SDH < 3.9 mmol/L were 1.72 (0.66-3.43) in CKD 1, 2.12 (0.85-4.55) in CKD 2, and 2.22 (1.09-4.57) in CKD 3 (p = 0.12). For SDH < 3.0 mmol/L, these rates were 0.20 (0.00-0.50), 0.21 (0.10-0.61), and 0.20 (0.00-0.71), respectively (p = 0.88). PRH events had medians of 1.05 (0.40-2.12), 1.31 (0.61-2.42), and 1.28 (0.68-2.25) for CKD 1, CKD 2, and CKD 3 (p = 0.24).
CONCLUSION: In people with insulin-treated T2DM and CKD stages 2 or 3, the rates of SDH and PRH do not significantly differ from those in people without CKD.
TRIAL REGISTRATION: ClinicalTRials.gov: NCT04304963.
MATERIALS AND METHOD: Insulin-treated T2D patients with > 1 hypoglycaemic episode within the last 3 months wore a blinded continuous glucose monitor (CGM) and recorded PRH on the bespoke Hypo-METRICS app for 10 weeks. SDH was defined as per consensus guidelines. The participants were grouped based on estimated glomerular filtration rate (eGFR), that is CKD 1 (eGFR ≥ 90 mL/min; n = 117), CKD 2 (eGFR 60-89 mL/min; n = 140), and CKD 3 (eGFR 30-59 mL/min; n = 56). We used descriptive statistics, Kruskal-Wallis rank sum tests, and a negative binomial models to control for confounders.
RESULTS: In total, 313 participants with T2DM were included. Median age increased with declining eGFR (p < 0.001). Median (IQR) events per week for SDH < 3.9 mmol/L were 1.72 (0.66-3.43) in CKD 1, 2.12 (0.85-4.55) in CKD 2, and 2.22 (1.09-4.57) in CKD 3 (p = 0.12). For SDH < 3.0 mmol/L, these rates were 0.20 (0.00-0.50), 0.21 (0.10-0.61), and 0.20 (0.00-0.71), respectively (p = 0.88). PRH events had medians of 1.05 (0.40-2.12), 1.31 (0.61-2.42), and 1.28 (0.68-2.25) for CKD 1, CKD 2, and CKD 3 (p = 0.24).
CONCLUSION: In people with insulin-treated T2DM and CKD stages 2 or 3, the rates of SDH and PRH do not significantly differ from those in people without CKD.
TRIAL REGISTRATION: ClinicalTRials.gov: NCT04304963.